In metastatic cancer, the expression of PD-L1, which binds to PD-1, has been correlated with disease progression and prognosis, suggesting a potentially pivotal role for PD-1/PD-L1 inhibitors in altering disease outcomes [16]. The gene discussed is CD274; the disease is metastatic malignant neoplasm.